aibioBridgeBio prices $550 million of 0.75% convertible notes to refinance 2027 debt
Tickers BBIO
The notes due 2033 carry a 45% conversion premium. Underwriters later took the full option, and BridgeBio bought back about 1.1 million shares alongside the sale.
Key facts
- Company
- BridgeBio Pharma, Inc. (NASDAQ: BBIO)
- News type
- Debt Financing
- Primary source
- BridgeBio Pharma
BridgeBio Pharma priced $550 million of 0.75% convertible senior notes due 2033 on Jan. 15, 2026, a private offering to qualified institutional buyers. The company said the purpose was to prefund repayment of its 2.50% convertible notes due 2027.
What happened
The notes pay interest twice a year, starting Aug. 1, 2026, and mature on Feb. 1, 2033. The initial conversion price is about $110.58 a share, a premium of roughly 45% over the $76.26 closing price on Jan. 15. Initial purchasers had an option for another $82.5 million of notes.
BridgeBio said the deal was "part of our strategy to lower interest expense, reduce dilution, and significantly extend debt maturity." It estimated net proceeds of about $538.4 million, or about $619.3 million with the option exercised in full.
Deal terms
The sale closed Jan. 21, and the purchasers took the option in full. An 8-K filed that day says BridgeBio issued $632.5 million of the notes and received net proceeds of about $619.3 million. The notes are senior unsecured obligations, convertible into cash, stock or a mix at BridgeBio's election.
According to the pricing exhibit, the company cannot redeem the notes before Feb. 6, 2030. After that it may redeem them for cash if the stock trades at or above 130% of the conversion price for a set period. Holders can require repurchase at par on certain events. The company also planned to spend about $82.5 million of cash to buy back about 1.1 million shares from some note purchasers at $76.26, and the 8-K puts the final figure at 1,081,825 shares. BridgeBio warned that such trades could affect the share price and could have raised the initial conversion price.
Proceeds go to repurchase, settle conversions of, or repay at maturity part of the 2027 notes, with the rest for general corporate purposes. The company gave no assurance on how much of the 2027 debt it will retire.
Why it matters
The deal swaps shorter, higher-coupon debt for longer, cheaper debt. The new coupon is 0.75% against 2.50%, and the maturity moves from 2027 to 2033. Dilution from conversion happens only if the stock rises well above $110.58.
BridgeBio is doing this as its first marketed drug grows. In its Jan. 12 JPMorgan conference update, the company reported preliminary net Attruby revenue of $146.0 million in the fourth quarter and $362.4 million for 2025, and cash of about $587.5 million at year end. It also said it intends to submit NDAs for BBP-418 in limb-girdle muscular dystrophy 2I/R9 and for encaleret in autosomal dominant hypocalcemia type 1 in the first half of 2026, and that topline results from the PROPEL 3 achondroplasia trial were expected by the end of the first quarter.
What it means for investors
Convertible debt is cheap because holders accept a low coupon (here 0.75%) in return for the right to share in upside. If the stock stays below the conversion price, BridgeBio repays principal in 2033 or earlier. If it rises above, existing holders share gains with noteholders. The company's concurrent buyback offsets some dilution but spends cash.
The risk is leverage. Total debt, per the 8-K, rises if the 2027 notes are not repurchased, and the filing makes no promise on that. The deal also bets on revenue growth. Fourth-quarter Attruby sales of $146.0 million are a base, but three more launches are planned and each costs money.
What to watch
The PROPEL 3 topline, expected by the end of the first quarter of 2026, and the two NDA submissions planned for the first half. Also how much of the 2027 notes BridgeBio retires, which later filings will disclose.